A retrospective study evaluating short efficacy and safety of apatinib in patients with advanced soft tissue sarcoma
Latest Information Update: 06 Jun 2017
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2017 New trial record
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology